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ABSTRACT 
 The aim of this study was to analyze ten (10) years of epidemiological surveillance data of meningitis in Burkina Faso for 
high risk germs patterns identification in order to contribute to the strengthening of prevention strategies. 
 A retrospective study of the past decade (2005- 2014) of cases of acute bacterial meningitis occurred in the thirteen health 
regions, collected through epidemiological surveillance data meningitis in Burkina Faso. From a total of 88 057 suspected 
cases of acute bacterial meningitis, we recorded 9134 deaths. From the laboratory confirmed cases, the identified germs were 
as follows: 56.79% of Neisseria meningitidis, 41.09% of Streptococcus pneumoniae and 2.13% of Haemophilus influenzae. 
Among the meningococcus isolated, we observed the following distribution: 23.11% of NmA, 58.84% of NmW and 18% of 
NmX. 
 Mortality associated with acute bacterial meningitis remains still high in Burkina Faso despite the complete disappearance 
of NmA since 2012, after the conjugate vaccine A (MenAfriVac) has been introduced in this country. However the 
emergence of NmX, the reemergence of NmW and the persistence of high prevalence of Streptococcus pneumoniae are a 
major concern in the fight against meningitis in Burkina Faso. So, it is necessary, in addition to the strengthening of 
surveillance, diagnosis and case management to develop and make available and accessible a conjugate trivalent vaccine 
against NmA the NmX and NmW serogroups. 
Keywords: meningococcal meningitis, W and X serogroups, Streptococcus pneumoniae, MenAfriVac. 
 
DYNAMIQUE DES GERMES RESPONSABLES DES MENINGITES BACTERIENNES 
AIGÜES AU BURKINA FASO DANS LES DIX DERNIERES ANNEES (2005-2014) 
 
RÉSUMÉ  
Contexte : l'objectif de cette étude était d’analyser  les données de la surveillance épidémiologique des méningites des dix 
(10) dernières années afin de dégager les profils de germes à risque en vue de contribuer au renforcement des stratégies de 
prévention  
Méthodes: Une étude rétrospective des dix dernières années (2005- 2014) sur les cas de méningites bactériennes aigues des 
treize régions sanitaires ;  recueillies à travers les données de  surveillance épidémiologique des méningites du Burkina 
Faso. 
Résultats: Sur un total de 88 057 cas suspects de méningites bactériennes aigues, nous avons enregistré 9134 décès. Parmi les 
cas confirmés au laboratoire, les germes identifiés se répartissent comme suit : 56.79%  de Neisseria meningitidis, 41.09% de 
Streptococcus pneumoniae  et 2.13% d’Haemophilus influenzae. Parmi les méningocoques, nous avons observé 23.11%  de 
NmA,  58.84% de NmW  et 18% de NmX.  
Conclusion: La mortalité associée aux méningites bactériennes aigues demeure toujours élevée au Burkina Faso malgré la 
disparition totale du  NmA depuis 2012 suite à l'introduction du vaccin conjugué A (MenAfriVac).  Cependant l’émergence 
de NmX, la réémergence de  NmW, et la persistance de la forte prévalence du Streptococcus pneumoniae constituent une 
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préoccupation majeure dans la lutte contre la méningite au Burkina Faso. Il s’avère donc  nécessaire, en plus du 
renforcement de la surveillance, du diagnostic et de la prise en charge des cas  de mettre au point et de rendre disponible et 
accessible un vaccin trivalent conjugué couvrant le NmA, le NmX et le NmW. 
Mots-clés: méningite à méningocoques, sérogroupes W et X,  Streptococcus pneumoniae, MenAfriVac. 
INTRODUCTION 
Acute bacterial meningitis is a major public health 
problem in the south-Sahara African area and 
particularly in Burkina Faso (1). This disease is a 
serious disease that can cause death within hours or 
may leave significant neurological sequelae (1, 2). 
Meningococcus is responsible for major epidemics, 
usually every 5-10 years, causing many cases of 
deaths in the population (3). More than half of the 
cases of meningococcal Neisseria meningitidis in the 
world occur in the African south-Sahara countries 
(4); they represent the 4th cause of mortality in 
under 15 years children, after malaria, diarrheal and 
respiratory diseases (3); according to the reports of 
the Directorate for the Fight against Disease (DLM), 
Burkina Faso recorded from 2006 to 2007 a lethality 
rate of 8% for meningitis (5). 
Prevention and response strategies are usually 
based on epidemiological surveillance, 
communication, proper case management and mass 
vaccination. In addition to serogroup A that was 
most responsible for epidemics before the 
MenAfriVac vaccine introduction, other serogroups 
have led to serious epidemics in Burkina Faso. This 
study aimed to analyze the ten (10) past years ie 
2005-2014 data of the epidemiological surveillance 
of meningitis in order to study trends and identify 
germs profiles at high risk for the upcoming years. 
This study could enable the Ministry of Health of 
Burkina Faso, especially the DLM in strengthening 
prevention of epidemic outbreaks. 
 
MATERIALS AND METHODS 
Study sites  
The study was conducted in thirteen (13) health 
regions of Burkina Faso: the Boucle of Mouhoun, 
the Cascades, the Centre, the Centre-East, the 
Centre-North, the Centre-West, the Centre-South, 
the East, the Hauts-Bassins, the North, the Plateau 
Central, the Sahel and the South-West regions. The 
country has a National Reference Laboratory for 
meningitis (NRL) that is the Charles De Gaulle 
University teaching Hospital laboratory of 
Bacteriology-Virology and four (4) national 
laboratories located in the University teaching 
Hospital of Yalgado Ouedraogo, the University 
teaching of Hospital Souro Sanou, the Centre Muraz 
and the National Laboratory of Public Health. Each 
region, through its health districts is affiliated to a 
laboratory for CSF analysis and isolation of germs. 
Type and period of the study 
The study was descriptive retrospective and was 
performed for analytical purposes. It covered ten 
years period, from January 2005 to December 2014. 
Sampling and sample  
The sampling method was exhaustive: the sample 
comprised of all cerebrospinal meningitis cases 
registered in the Ministry of Health database 
(national epidemiological surveillance system) 
during the study period. 
Cases of cerebrospinal meningitis of all health 
regions were selected and classified as suspected 
and confirmed cases, in accordance with the WHO 
definition of acute bacterial meningitis. 
Data collection 
Data was collected for analysis purpose on an 
especially designed form for each case. Clinical 
records, case filings forms, sampling bulletins and 
CSF analysis results were the primary tools for data 
collection. 
Results 
From 2005-2014, Burkina Faso recorded a lethality 
rate of 10.37 %. 5775 (6.55 %) of these suspected 








TABLE I- DISTRIBUTION OF MENINGITIS CASES AND DEATHS (LETHALITY) ACCORDING THE YEAR 
(N = 88,057) 
Year Suspected cases (N) Deaths  (N) Lethality (%) 
2005 3623 751 20.72 
2006 19162 1677 8.75 
2007 25695 1865 7.25 
2008 10345 1068 10.32 
2009 4878 693 14.20 
2010 6837 989 14.46 
2011 3878 588 15.16 
2012 7022 739 10.52 
2013 2984 367 12.29 
2014 3633 397 10.92 
Total 88 057 9 134 10.37 
The 2010 lethality rate was almost the double of that observed in 2007 or 2006 
Prevalence of identified germs from 2005 to 2014 
Among the confirmed cases, 3280 (3280/5775, that is 
to say 56.79%) were Neisseria meningitidis. The 
serogroups distribution was as follows: 23.11% 
(758/3280) of NmA, 58.84% (1930/3280) of NmW 
and 18% (591/3280) of NmX. Streptococcus 
pneumoniae and Haemophilus influenzae represented 
respectively 41.09% (2373/5775) and 2.13% 
(123/5775) of laboratory-confirmed cases. 
 
TABLE II: GERMS DISTRIBUTION OF ACCORDING TO THE YEAR (N =5775) 
 NmA 


























2006 244 (89.37) 
 
3 (1.09) 0 (0) 20 (7.32) 6 (2.19) 273 




























































































































































FIGURE 1: GERMS DISTRIBUTION ACCORDING TO THE YEAR, FROM 2005 TO 2014
  
TABLE III: DISTRIBUTION OF GERMS ACCORDING TO HEALTH REGIONS FROM 2005 TO 2014
 
Health region NmA NmW
Boucle of Mouhoun 57 254 




























Sahel 9 60 



























(N = 5775) 
 NmX Spn Hib 
55 271 8 
20 98 3 
16 93 8 
70 272 18 
29 168 11 
25 236 13 
63 124 5 
24 214 17 
81 311 3 
149 231 13 
43 220 11 
4 70 12 
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FIGURE 2: DYNAMICS OF GERMS DISTRIBUTION ACCORDING TO THE HEALTH REGION
 
DISCUSSION 
Among the suspected cases, the bacterial meningitis 
were laboratory-confirmed for 5775 patients, 
equivalent to about one patient in 15. One limitation 
of our study is related to the low rate of laboratory 
confirmed cases: less than 7% of cases have been 
laboratory confirmed. Several studies reveal the 
insufficient use of the laboratory in meningitis 
surveillance in the meningitidis belt countries (6, 7). 
This situation could be explained by the integrated 
surveillance system set up in Burkina Faso before 
the introduction of the serogroup A anti 
meningococcal conjugate vaccine, the MenAfriVac 
in 2010. Since mass vaccination with MenAfriVac, 
the country adopted a surveillance system in which 
the CSF analysis of each suspected case is 
mandatory. In addition, since 2010 the use of real
time PCR increased the laboratories capacities for 
meningitidis detection. 
During the 2005 to 2014 period, 88 057 meningitis 
suspected cases have been recorded in the 13 health 
regions of Burkina Faso. The years  2013 and 2014 
were relatively calm with fewer cases (6617) in 
contrast to  years  2006 and 2007 when the number 
of reported cases was 6 times higher (44,857).
Analysis of epidemiological surveillance data from 
2005 to 2014 showed that Neisseria meningitidis
the most responsible of meningitis in Burkina Faso, 
about 57% of laboratory-confirmed cases. 
finding confirms what Leon Lapeyssonnie described 
since 1963 on germs that cause acute bacterial 
meningitis in the countries of the meningitidis belt 
in which Burkina Faso is entirely included (4, 8).
The NmA has been the dominant serogroup till 2008 
with its peak in 2007: about 90% (253/282) of NmA 









addition to Burkina Faso, other countries located in 
the meningitidis belt were hit hard in 2007 by the 
NmA including Sudan and Uganda that notified 
from January 1st to March 16th, 2007, respectively 
7149 and 3297 cases, mainly due to NmA (7).
Of all NmA isolated over the past 10 yea
Centre health region which houses the capital of 
Burkina Faso is one that recorded the highest 
prevalence of serogroup with about 20% (149/758) 
of NmA. This observation could be explained by the 
fact that this region is the main convergence area fo
both local and foreign populations in order to 
engage in economic activities. 
Of note, the country experienced from 2010 to 2012 
an abrupt emergence of a new serogroup, the NmX 
that was, until that period absent from the country 
where 566 cases of NmX with 207 cases in 2010 and 
201 serogroup 2012 have been recorded. 
serogroup had been reported in other countries of 
the belt meningitidis since 2006 including Niger, 
Togo, Ghana and Kenya (9, 10, 11, 12, 13). A part 
from Kenya, Niger, Togo and Ghana are
border countries at the east and the south and thus, 
population movement between Burkina Faso and its 
border countries could explain the spread of this 
serogroup in almost all the 13 health regions that 
have been affected. Contrarily to the other 
serogroups, no vaccine is yet available against the 
NmX; in effect since December 2010, Burkina Faso, 
like other countries of the meningitidis belt 
introduced nationwide a conjugate vaccine against 
serogroup A, the MenAfriVac. Since 2011 we have 
seen the almost total disappearance of NmA: only 
0.35% of NmA (4/1114) and no case of this 
serogroup have been reported since this year. 











vaccine on cerebrospinal meningitis as well as on 
the NmA asymptomatic carriage.(14, 15, 16, 17). 
Further, the study revealed the re-emergence of the 
NmW serogroup after vaccination. From 2011, a 
progressive increase in this serogroup was observed 
with a peak in 2012: approximately 65% (1357/2089) 
of germs confirmed during this year (2012). The 
number of cases declined in 2013 and 2014 but 
remained still high: respectively 236 and 213 cases. 
Out of all the affected regions, the regions of Hauts 
Bassins, Center-East and boucle du Mouhoun were 
the most affected with respectively 18.29% 
(353/1930), 13.57% (262/1930) and 13.16% ( 
254/1930) of meningitidis cases caused by NmW 
from 2005 to 2014. Of note, in addition to Burkina 
Faso, countries such as, Benin, Mali, Nigeria, 
Gambia, Guinea and Sudan have experienced 
epidemics due to the NmW after MenAfriVac 
vaccination (18, 19, 20, 21). The proximity of some 
health regions with neighboring countries such as 
Hauts Bassins and Boucle du Mouhoun regions that 
are  adjacent to Mali as well as the center-East 
region, that is near to  Benin; could explain their 
high exposure to the NmW. Of note, this serogroup 
was isolated for the first time in Burkina Faso in 
2002 - 2003 causing high morbidity and mortality 
(22, 23). Our study showed a very high lethality rate 
in 2012 where about 65% of the isolates have been 
identified as NmW. Indeed in 2012, we recorded a 
lethality rate 10.52% with 739 deaths out of 7022 
cases as well as in 2010 when the lethality rate was 
14.46% with 989 deaths out of 6837 cases of 
meningitis. This year, 77.23% (207/268) of the 
isolates were related to NmX. In general, we found 
that the lethality due to NmX and NmW is 
equivalent or even higher than that caused by 
NmA; this finding has been revealed by other 
authors (21, 24, 25). 
Besides the Neisseria meningitidis, the study has 
shown the significant proportion of Streptococcus 
pneumoniae (41.09%) in the occurrence of 
cerebrospinal meningitis during the past decade in 
Burkina Faso. This germ, well-known for its high 
lethality (26, 27) has been observed since 2009; 
however it had a net increase after vaccination with 
MenAfriVac. In 2011, it represented almost 72% 
(798/1114) of the isolates; during  the same year we 
have recorded 3878 cases of meningitis with 588 
deaths, that is to say a lethality rate of 15.16%. Since 
2011, there has been noticed a decrease of cases but 
the number of cases remained high from 2012 to 
2014: it was respectively 502 cases in 2012, 351 in 
2013 and 507 cases in 2014. 
In addition to the three (03) most affected health 
regions by the NmW, other regions such as the 
Centre-West, North and Plateau Central regions had 
shown a high number of cases Spn. 
 
CONCLUSION 
Cerebrospinal meningitis continues to cause high 
mortality in Burkina Faso population although no 
NmA case has been isolated since 2011, reflecting 
effective action of MenAfriVac vaccination against 
this serogroup. However the emergence of NmX 
serogroup in 2010 and re-emergence of NmW 
serogroup since 2012 remain a major concern in the 
fight against meningococcal meningitis. In addition, 
the study has identified Streptococcus pneumoniae as 
a significant cause of high mortality of cerebrospinal 
meningitis in Burkina Faso. If a  vaccine against 
NmX has not yet been developed , a conjugate 
vaccine against pneumococcus, which takes into 
account most of Spn serotypes encountered in 
Burkina Faso has been introduced  in the childhood 
immunization program since 2013,. Similarly, 
polysaccharide vaccine against the NmW serogroup 
exists but has a limited access for developing 
countries populations such as Burkina Faso. Given 
this change in the epidemiological situation that is 
heterogeneous and dynamic geographically and 
through years, highlighting the emergence of NmX, 
the reemergence of NmW, and the persistence of 
high prevalence of Streptococcus pneumoniae, it 
appears imperative to reinforce preventive and case 
management strategies. 
Thus, in addition to the strengthening of the 
surveillance which is essential to monitor these 
changes and remain able to detect epidemics caused 
by every serogroup of Nm; it is imperative to 
develop a trivalent conjugated vaccine covering 
NmA, NmX, and NmW serogroups and to make it 
available to the population. Such vaccine would be 
particularly useful for the prevention of 
meningococcal disease in the African meningitis belt 
and could protect against more than 90% of invasive 
cases of meningococcal meningitis. The major 
challenge after the vaccine development would be 
for the country to integrate it systematically into the 
national immunization program. 
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